Heron Therapeutics (HRTX) Competitors $1.28 +0.01 (+0.79%) Closing price 09/11/2025 04:00 PM EasternExtended Trading$1.30 +0.01 (+1.17%) As of 09/11/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock HRTX vs. IOVA, TSHA, NAGE, AVBP, DAWN, DNTH, VALN, DNA, TNGX, and GYREShould you be buying Heron Therapeutics stock or one of its competitors? The main competitors of Heron Therapeutics include Iovance Biotherapeutics (IOVA), Taysha Gene Therapies (TSHA), Niagen Bioscience (NAGE), ArriVent BioPharma (AVBP), Day One Biopharmaceuticals (DAWN), Dianthus Therapeutics (DNTH), Valneva (VALN), Ginkgo Bioworks (DNA), Tango Therapeutics (TNGX), and Gyre Therapeutics (GYRE). These companies are all part of the "pharmaceutical products" industry. Heron Therapeutics vs. Its Competitors Iovance Biotherapeutics Taysha Gene Therapies Niagen Bioscience ArriVent BioPharma Day One Biopharmaceuticals Dianthus Therapeutics Valneva Ginkgo Bioworks Tango Therapeutics Gyre Therapeutics Iovance Biotherapeutics (NASDAQ:IOVA) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation. Do institutionals & insiders have more ownership in IOVA or HRTX? 77.0% of Iovance Biotherapeutics shares are held by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are held by institutional investors. 10.3% of Iovance Biotherapeutics shares are held by company insiders. Comparatively, 5.9% of Heron Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Do analysts prefer IOVA or HRTX? Iovance Biotherapeutics currently has a consensus price target of $11.90, indicating a potential upside of 391.74%. Heron Therapeutics has a consensus price target of $4.50, indicating a potential upside of 251.56%. Given Iovance Biotherapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Iovance Biotherapeutics is more favorable than Heron Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iovance Biotherapeutics 1 Sell rating(s) 7 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.36Heron Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Is IOVA or HRTX more profitable? Heron Therapeutics has a net margin of -0.62% compared to Iovance Biotherapeutics' net margin of -161.44%. Heron Therapeutics' return on equity of 0.00% beat Iovance Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Iovance Biotherapeutics-161.44% -52.87% -41.31% Heron Therapeutics -0.62%N/A -0.40% Which has better valuation and earnings, IOVA or HRTX? Heron Therapeutics has lower revenue, but higher earnings than Iovance Biotherapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIovance Biotherapeutics$164.07M5.34-$372.18M-$1.23-1.97Heron Therapeutics$149.69M1.31-$13.58M-$0.02-64.00 Which has more risk & volatility, IOVA or HRTX? Iovance Biotherapeutics has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500. Comparatively, Heron Therapeutics has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500. Does the media favor IOVA or HRTX? In the previous week, Iovance Biotherapeutics had 1 more articles in the media than Heron Therapeutics. MarketBeat recorded 7 mentions for Iovance Biotherapeutics and 6 mentions for Heron Therapeutics. Heron Therapeutics' average media sentiment score of 1.39 beat Iovance Biotherapeutics' score of 1.14 indicating that Heron Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Iovance Biotherapeutics 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Heron Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryIovance Biotherapeutics and Heron Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get Heron Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HRTX vs. The Competition Export to ExcelMetricHeron TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$194.68M$2.55B$5.78B$10.07BDividend YieldN/A56.65%5.69%4.62%P/E Ratio-64.0023.7675.3726.21Price / Sales1.31564.68471.1491.61Price / CashN/A169.2537.0859.91Price / Book-5.825.3911.906.28Net Income-$13.58M$32.95M$3.29B$270.85M7 Day Performance-2.29%2.61%1.49%3.58%1 Month Performance-2.29%9.87%7.72%6.67%1 Year Performance-30.43%1.49%59.32%27.73% Heron Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HRTXHeron Therapeutics4.2693 of 5 stars$1.28+0.8%$4.50+251.6%-29.3%$194.68M$149.69M-64.00300Positive NewsIOVAIovance Biotherapeutics4.2175 of 5 stars$2.23flat$11.90+433.6%-74.1%$806.93M$164.07M-1.81500Positive NewsTSHATaysha Gene Therapies1.9349 of 5 stars$2.92+3.2%$8.29+183.8%+39.7%$796.56M$8.10M-8.59180NAGENiagen Bioscience2.022 of 5 stars$9.90+0.8%$13.42+35.6%N/A$789.53M$99.60M47.15120Analyst DowngradeAVBPArriVent BioPharma1.972 of 5 stars$19.12-0.5%$39.14+104.7%-25.0%$775.70MN/A-4.7640Positive NewsDAWNDay One Biopharmaceuticals2.9627 of 5 stars$7.51-1.1%$25.29+236.7%-47.7%$769.25M$131.16M-7.9160Positive NewsDNTHDianthus Therapeutics2.9161 of 5 stars$23.57-5.0%$54.00+129.1%+37.3%$758.72M$6.24M-7.2580Trending NewsAnalyst ForecastInsider TradeGap DownVALNValneva2.798 of 5 stars$8.85+0.1%$15.33+73.3%+31.1%$753.05M$183.52M-9.03700Analyst ForecastShort Interest ↓DNAGinkgo Bioworks1.7497 of 5 stars$12.71+4.4%$9.50-25.3%+67.9%$752.49M$230.82M-2.17640Positive NewsTNGXTango Therapeutics1.8318 of 5 stars$6.71-1.6%$10.50+56.5%-29.4%$746.56M$42.07M-5.0590News CoveragePositive NewsInsider TradeGYREGyre Therapeutics1.6671 of 5 stars$7.74-6.5%$18.00+132.6%-41.1%$745.44M$105.76M774.7740News CoverageAnalyst Revision Related Companies and Tools Related Companies Iovance Biotherapeutics Competitors Taysha Gene Therapies Competitors Niagen Bioscience Competitors ArriVent BioPharma Competitors Day One Biopharmaceuticals Competitors Dianthus Therapeutics Competitors Valneva Competitors Ginkgo Bioworks Competitors Tango Therapeutics Competitors Gyre Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HRTX) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Strange Looking Box Behind Nvidia’s Massive Run?Inside this unremarkable box lies the technology that powers NVIDIA's newest Superchip - the one set to domina...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Heron Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Heron Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
